Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 284

1.

Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: presentation and response to treatment.

Aversa SM, Stragliotto S, Marino D, Calabrese F, Rigotti P, Marchini F, Gambino A, Feltrin G, Boso C, Canova F, Soldà C, Mazzarotto R, Burra P.

Acta Haematol. 2008;120(1):36-46. doi: 10.1159/000155234. Epub 2008 Sep 16.

PMID:
18797163
2.

Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.

Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E; Cooperative Study Group on PTLDs.

Haematologica. 2002 Jan;87(1):67-77.

3.

Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.

Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dörken B, Oertel S.

Transplantation. 2007 Apr 15;83(7):912-8.

PMID:
17460562
4.

Post-transplant lymphoproliferative disorders (PTLD) after renal transplantation: management and evolution of seven cases among 1002 renal transplants in São Paulo, Brazil.

Colleoni GW, Oliveira JS, Borducchi DM, Fernandes MA, Da Silva HT, Alves AC, De Franco MF, Kerbauy J, Pestana JO.

Leuk Lymphoma. 2000 Sep;39(1-2):145-50.

PMID:
10975393
5.

Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation.

Taylor AL, Bowles KM, Callaghan CJ, Wimperis JZ, Grant JW, Marcus RE, Bradley JA.

Transplantation. 2006 Aug 15;82(3):375-81.

PMID:
16906036
6.

Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience.

Marino D, Burra P, Boccagni P, Calabrese F, Canova F, Trentin C, Boso C, Soldà C, Angeli P, Aversa SM.

Anticancer Res. 2010 Jun;30(6):2383-91.

PMID:
20651397
7.

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients.

Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, Schuster SJ, Porter DL, Montone KT, Stadtmauer EA.

Transplantation. 2001 Apr 27;71(8):1076-88.

PMID:
11374406
8.

Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.

Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC.

J Clin Oncol. 2005 Sep 20;23(27):6481-8.

PMID:
16170157
9.

Long-term survival after post-transplant lymphoproliferative disease in children.

Nathanson S, Debray D, Delarue A, Deschênes G.

Pediatr Nephrol. 2002 Aug;17(8):668-72. Epub 2002 Jun 7.

PMID:
12185479
10.

Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.

Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaeglé ML, Meyer C, Epailly E, Chenard MP, Lioure B, Natarajan-Ame S, Maloisel F, Lutun P, Kessler R, Moulin B, Bergerat JP, Wolf P, Herbrecht R.

Br J Haematol. 2006 Sep;134(6):602-12. Epub 2006 Aug 2.

PMID:
16889621
11.

Posttransplant lymphoproliferative disease: treatment and outcome in renal transplant recipients.

Soler MJ, Puig JM, Mir M, Parrilla J, Pedro C, Salar A, Serrano S, Lloveras J.

Transplant Proc. 2003 Aug;35(5):1709-13.

PMID:
12962767
12.
13.

Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.

Trappe R, Hinrichs C, Appel U, Babel N, Reinke P, Neumayer HH, Budde K, Dreyling M, Dührsen U, Kliem V, Schüttrumpf S, Hauser IA, Mergenthaler HG, Schlattmann P, Anagnostopoulos I, Doerken B, Riess H.

Am J Transplant. 2009 Oct;9(10):2331-7. doi: 10.1111/j.1600-6143.2009.02772.x. Epub 2009 Aug 6.

14.

Treatment of PTLD with rituximab or chemotherapy.

Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthoff KM, Schuster SJ, Nasta SD, Stadtmauer EA, Tsai DE.

Am J Transplant. 2006 Mar;6(3):569-76.

15.

Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Váry M, Babel N, Trappe RU, Jonas S, Hummel M, Anagnostopoulos I, Dörken B, Riess HB.

Am J Transplant. 2005 Dec;5(12):2901-6.

16.

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.

Choquet S, Trappe R, Leblond V, Jäger U, Davi F, Oertel S.

Haematologica. 2007 Feb;92(2):273-4.

17.
18.

Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.

Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.

Pediatr Transplant. 2009 Feb;13(1):54-62. doi: 10.1111/j.1399-3046.2008.00969.x. Epub 2008 Jun 1.

PMID:
18518912
19.

Posttransplant lymphoproliferative disorder: morphological picture and diagnostic difficulties.

Ziarkiewicz-Wróblewska B, Górnicka B, Suleiman W, Ołdakowska-Jedynak U, Wróblewski T, Bogdańska M, Ziółkowski J, Nowacka-Cieciura E, Foroncewicz B, Pileri SA, Durlik M, Paczek L, Krawczyk M, Wasiutyński A.

Transplant Proc. 2006 Jan-Feb;38(1):168-72.

PMID:
16504694
20.

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.

González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF; GEL/TAMO (Grupo Español de Linfomas); GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear); GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas).

Haematologica. 2007 Nov;92(11):1489-94.

Supplemental Content

Support Center